Edition:
United States

Genomic Health Inc (GHDX.O)

GHDX.O on Nasdaq

30.01USD
2 Dec 2016
Change (% chg)

$0.44 (+1.49%)
Prev Close
$29.57
Open
$29.53
Day's High
$30.29
Day's Low
$29.20
Volume
127,162
Avg. Vol
209,457
52-wk High
$35.79
52-wk Low
$22.00

Summary

Name Age Since Current Position

Kimberly Popovits

56 2012 Chairman of the Board, President, Chief Executive Officer

Gordon Cole

60 2014 Chief Financial Officer, Chief Operating Officer, Secretary

Steven Shak

64 2014 Chief Scientific Officer

Julian Baker

50 2012 Lead Independent Director

Geoffrey Parker

51 2016 Director

Felix Baker

47 2012 Independent Director

Fred Cohen

59 2002 Independent Director

Henry Fuchs

58 2013 Independent Director

Ginger Graham

60 2008 Independent Director

Randy Livingston

61 2004 Independent Director

Biographies

Name Description

Kimberly Popovits

Ms. Kimberly J. Popovits is Chairman of the Board, President, Chief Executive Officer of Genomic Health, Inc. Ms. Popovits served in various roles at Genentech, Inc., a biotechnology company, most recently serving as Senior Vice President, Marketing and Sales from February 2001 to February 2002, and as Vice President, Sales from October 1994 to February 2001. Prior to joining Genentech, Ms. Popovits served as Division Manager, Southeast Region, for American Critical Care, a Division of American Hospital Supply, a supplier of healthcare products to hospitals. In addition, Ms. Popovits served as a director of Nuvelo, Inc. from July 2005 until its merger with ARCA biopharma, Inc. in January 2009.

Gordon Cole

Mr. G. Bradley Cole is Chief Financial Officer, Chief Operating Officer, Principal Financial Officer, Principal Accounting Officer of Genomic Health, Inc. he served in various roles at Guidant Corporation, a medical device company, most recently serving as Vice President, Finance and Business Development for the Endovascular Solutions Group from January 2001 until May 2004. From July 1994 to December 1997, Mr. Cole was Vice President, Finance and Chief Financial Officer of Endovascular Technologies, Inc., a medical device company that was acquired by Guidant Corporation. From December 1988 to February 1994, he served as Vice President, Finance and Chief Financial Officer of Applied Biosystems Incorporated, a life sciences systems company. Mr. Cole holds a B.S. in Business from Biola University and an M.B.A. from San Jose State University.

Steven Shak

Dr. Steven Shak, M.D., is Chief scientific officer of Genomic Health, Inc. From July 1996 to October 2000, Dr. Shak served in various roles in Medical Affairs at Genentech, most recently as Senior Director and Staff Clinical Scientist. From November 1989 to July 1996, Dr. Shak served as a Director of Discovery Research at Genentech, where he was responsible for Pulmonary Research, Immunology, and Pathology. Prior to joining Genentech, Dr. Shak was an Assistant Professor of Medicine and Pharmacology at the New York University School of Medicine. Dr. Shak holds a B.A. in Chemistry from Amherst College and an M.D. from the New York University School of Medicine, and completed his post-doctoral training at the University of California, San Francisco.

Julian Baker

Dr. Julian C. Baker has been appointed as Lead Independent Director of Genomic Health, Inc., effective March 1, 2012. He is a Managing Partner of Baker Brothers Investments, which he and his brother, Felix Baker, Ph.D., founded in 2000. Mr. Baker's firm manages long-term investment funds, focused on publicly traded life sciences companies, for major university endowments and foundations. Mr. Baker's career as a fund-manager began in 1994 when he co-founded a biotechnology investing partnership with the Tisch Family. Previously, Mr. Baker was employed from 1988 to 1993 by the private equity investment arm of Credit Suisse First Boston Corporation. Mr. Baker is also a director of Incyte Corporation. Mr. Baker served as a director of Trimeris, Inc. from April 2004 until November 2011.

Geoffrey Parker

Mr. Geoffrey M. Parker is Director of the Company. Mr. Parker served as the Executive Vice President and Chief Financial Officer of Anacor Pharmaceuticals, Inc., a biopharmaceutical company focused on small-molecule therapeutics, from May 2014 to May 2015 and was Senior Vice President and Chief Financial Officer at Anacor from September 2010 to May 2014. From April 1997 to April 2009, Mr. Parker was a Vice President, Managing Director and Partner at the global investment banking and securities firm Goldman, Sachs & Co., leading their West Coast Healthcare Investment Banking practice during this time. Mr. Parker also served in various capacities with Goldman, Sachs & Co. from 1990 to 1995 and 1986 to 1988. From 1995 to 1997, Mr. Parker was Vice President at Feibusch & Co., a venture capital firm in Larkspur, California. Mr. Parker is currently a member of the board of directors of ChemoCentryx, Inc. and Sunesis Pharmaceuticals, Inc. Mr. Parker received an A.B. from Dartmouth College in Engineering Sciences and Economics and an M.B.A. from the Stanford Graduate School of Business.

Felix Baker

Dr. Felix J. Baker, Ph.D., is appointed as the Director of Genomic Health, Inc. Dr. Baker's firm manages long-term investment funds, focused on publicly traded life sciences companies, for major university endowments and foundations. Dr. Baker's career as a fund-manager began in 1994 when he co-founded a biotechnology investing partnership with the Tisch Family. Dr. Baker is also a director of Seattle Genetics, Inc., where he serves as lead independent director, and serves as the Chairman of the Board of Synageva, Inc. Dr. Baker served as a director of Ardea Biosciences, Inc. from February 2010 until its acquisition in June 2012, and a director of Trimeris, Inc. from April 2004 until November 2011.

Fred Cohen

Dr. Fred E. Cohen, M.D., D.Phil., is Independent Director of Genomic Health, Inc. He is a partner at TPG, a private equity firm he joined in 2001, and serves as co-head of TPG's biotechnology group. Dr. Cohen was an Adjunct Professor of Cellular and Molecular Pharmacology at the University of California, San Francisco. Dr. Cohen serves as a director of BioCryst Pharmaceuticals, Inc., CareDx, Inc., Five Prime Therupeutics, Inc., Quintiles Transnational Holdings Inc., Roka Bioscience, Inc., Tandem Diabetes Care, Inc., Veracyte, Inc. and a number of privately held companies.

Henry Fuchs

Dr. Henry J. Fuchs M.D.,Ph.D., has been appointed as Independent Director of Genomic Health, Inc., effective September 17, 2013. Dr. Fuchs was Executive Vice President and Chief Medical Officer of Onyx Pharmaceuticals, Inc., a biopharmaceutical company from September 2005 to December 2008 and served in multiple roles of increasing responsibility at Ardea Biosciences, Inc., a biotechnology company, first as Vice President, Clinical Affairs, then as President and Chief Operating Officer, and finally as President and Chief Executive Officer, from October 1996 until June 2005. From 1987 to 1996, Dr. Fuchs held various positions at Genentech Inc., a biotechnology company. Dr. Fuchs serves as a director of Mirati Therapeutics, Inc. and served as a director of Ardea Biosciences, Inc. from November 2001 to June 2012.

Ginger Graham

Ms. Ginger L. Graham is Independent Director of Genomic Health, Inc. She has served as Faculty at Harvard Business School since October 2009 and as President and Chief Executive Officer of Two Trees Consulting, a healthcare and executive leadership consulting firm, since November 2007. Ms. Graham served as Faculty at Harvard Business School from October 2009 to June 2012 and was Chief Executive Officer of Amylin Pharmaceuticals, Inc., a biopharmaceutical company, from September 2003 to March 2007, and served as Amylin's President from September 2003 to June 2006. From 1994 to 2003, Ms. Graham held various positions with Guidant Corporation, including Group Chairman, Office of the President, President of the Vascular Intervention Group, and Vice President. From 1979 to 1994, Ms. Graham held various positions with Eli Lilly and Company, including President and Chief Executive Officer of Advanced Cardiovascular Systems, Inc. Ms. Graham currently serves as a director of Clovis Oncology, Inc., Walgreen Co. and a number of privately held companies. Ms. Graham served as a director of Amylin Pharmaceuticals, Inc. from November 1995 to May 2009.

Randy Livingston

Mr. Randall S. Livingston is Independent Director of Genomic Health, Inc. He has served as Vice President for Business Affairs and Chief Financial Officer of Stanford University since 2001. Prior to 2001, Mr. Livingston spent 16 years working in Silicon Valley with several technology and life science companies as Chief Financial Officer and in various corporate development and marketing roles. Mr. Livingston currently serves as a director of eHealth, Inc. and Pacific Biosciences, Inc.

Basic Compensation

Options Compensation

Name Options Value

Kimberly Popovits

195,192 1,942,992

Gordon Cole

251,238 2,422,299

Steven Shak

133,348 1,006,610

Julian Baker

0 0

Geoffrey Parker

0 0

Felix Baker

0 0

Fred Cohen

0 0

Henry Fuchs

0 0

Ginger Graham

0 0

Randy Livingston

0 0